• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G/A filed by Coherus BioSciences Inc. (Amendment)

    2/14/24 4:58:16 PM ET
    $CHRS
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Get the next $CHRS alert in real time by email
    SC 13G/A 1 tm243953d7_sc13ga.htm SC 13G/A

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

    SCHEDULE 13G*

    (Rule 13d-102)

     

    INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT

    TO § 240.13d-1(b), (c), AND (d) AND AMENDMENTS THERETO FILED

    PURSUANT TO § 240.13d-2

    (Amendment No. 1)*

     

     

    Coherus BioSciences, Inc.
    (Name of Issuer)
     
    Common Stock, $0.0001 par value per share (the “Shares”)
    (Title of Class of Securities)
     
    19249H103
    (CUSIP Number)
     
    December 31, 2023
    (Date of Event Which Requires Filing of the Statement)

     

     

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

     

    o Rule 13d-1(b)
    x Rule 13d-1(c)
    o Rule 13d-1(d)

     

    * The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

     

     

    The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     

     

     

     

     

    CUSIP No. 19249H103 13G Page 2 of 13 Pages

     

     

    1.

    NAME OF REPORTING PERSONS

     

    Citadel Advisors LLC

    2.

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

    (a)     o

    (b)     o

     

    3.

    SEC USE ONLY

     

    4.

    CITIZENSHIP OR PLACE OF ORGANIZATION

     

    Delaware

    NUMBER OF
    SHARES
    BENEFICIALLY
    OWNED BY
    EACH
    REPORTING
    PERSON
    WITH
    5.

    SOLE VOTING POWER

     

    0

    6.

    SHARED VOTING POWER

     

    1,751,103 Shares

    7.

    SOLE DISPOSITIVE POWER

     

    0

    8.

    SHARED DISPOSITIVE POWER

     

    See Row 6 above

    9.

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

    See Row 6 above

    10.

    CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES

    o

     

    11.

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

     

    1.6%1

    12.

    TYPE OF REPORTING PERSON

     

    IA; OO; HC

           

     

    _________________________

    1 The percentages reported in this Schedule 13G are based upon 111,364,152 Shares outstanding as of October 31, 2023 (according to the issuer’s Form 10-Q as filed with the Securities and Exchange Commission on November 6, 2023).

     

     

     

     

     

    CUSIP No. 19249H103 13G Page 3 of 13 Pages

     

     

    1.

    NAME OF REPORTING PERSONS

     

    Citadel Advisors Holdings LP

    2.

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

    (a)     o

    (b)     o

     

    3.

    SEC USE ONLY

     

    4.

    CITIZENSHIP OR PLACE OF ORGANIZATION

     

    Delaware

    NUMBER OF
    SHARES
    BENEFICIALLY
    OWNED BY
    EACH
    REPORTING
    PERSON
    WITH
    5.

    SOLE VOTING POWER

     

    0

    6.

    SHARED VOTING POWER

     

    1,751,103 Shares

    7.

    SOLE DISPOSITIVE POWER

     

    0

    8.

    SHARED DISPOSITIVE POWER

     

    See Row 6 above

    9.

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

    See Row 6 above

    10.

    CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES

    o

     

    11.

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

     

    1.6%

    12.

    TYPE OF REPORTING PERSON

     

    PN; HC

           

     

     

     

     

     

    CUSIP No. 19249H103 13G Page 4 of 13 Pages

     

     

    1.

    NAME OF REPORTING PERSONS

     

    Citadel GP LLC

    2.

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

    (a)     o

    (b)     o

     

    3.

    SEC USE ONLY

     

    4.

    CITIZENSHIP OR PLACE OF ORGANIZATION

     

    Delaware

    NUMBER OF
    SHARES
    BENEFICIALLY
    OWNED BY
    EACH
    REPORTING
    PERSON
    WITH
    5.

    SOLE VOTING POWER

     

    0

    6.

    SHARED VOTING POWER

     

    1,751,103 Shares

    7.

    SOLE DISPOSITIVE POWER

     

    0

    8.

    SHARED DISPOSITIVE POWER

     

    See Row 6 above

    9.

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

    See Row 6 above

    10.

    CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES

    o

     

    11.

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

     

    1.6%

    12.

    TYPE OF REPORTING PERSON

     

    OO; HC

           

     

     

     

     

     

    CUSIP No. 19249H103 13G Page 5 of 13 Pages

     

     

    1.

    NAME OF REPORTING PERSONS

     

    Citadel Securities LLC

    2.

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

    (a)     o

    (b)     o

     

    3.

    SEC USE ONLY

     

    4.

    CITIZENSHIP OR PLACE OF ORGANIZATION

     

    Delaware

    NUMBER OF
    SHARES
    BENEFICIALLY
    OWNED BY
    EACH
    REPORTING
    PERSON
    WITH
    5.

    SOLE VOTING POWER

     

    0

    6.

    SHARED VOTING POWER

     

    119,325 Shares

    7.

    SOLE DISPOSITIVE POWER

     

    0

    8.

    SHARED DISPOSITIVE POWER

     

    See Row 6 above

    9.

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

    See Row 6 above

    10.

    CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES

    o

     

    11.

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

     

    0.1%

    12.

    TYPE OF REPORTING PERSON

     

    BD; OO

           

     

     

     

     

     

    CUSIP No. 19249H103 13G Page 6 of 13 Pages

     

     

    1.

    NAME OF REPORTING PERSONS

     

    Citadel Securities Group LP

    2.

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

    (a)     o

    (b)     o

     

    3.

    SEC USE ONLY

     

    4.

    CITIZENSHIP OR PLACE OF ORGANIZATION

     

    Delaware

    NUMBER OF
    SHARES
    BENEFICIALLY
    OWNED BY
    EACH
    REPORTING
    PERSON
    WITH
    5.

    SOLE VOTING POWER

     

    0

    6.

    SHARED VOTING POWER

     

    296,183 Shares

    7.

    SOLE DISPOSITIVE POWER

     

    0

    8.

    SHARED DISPOSITIVE POWER

     

    See Row 6 above

    9.

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

    See Row 6 above

    10.

    CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES

    o

     

    11.

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

     

    0.3%

    12.

    TYPE OF REPORTING PERSON

     

    PN; HC

           

     

     

     

     

     

    CUSIP No. 19249H103 13G Page 7 of 13 Pages

     

     

    1.

    NAME OF REPORTING PERSONS

     

    Citadel Securities GP LLC

    2.

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

    (a)     o

    (b)     o

     

    3.

    SEC USE ONLY

     

    4.

    CITIZENSHIP OR PLACE OF ORGANIZATION

     

    Delaware

    NUMBER OF
    SHARES
    BENEFICIALLY
    OWNED BY
    EACH
    REPORTING
    PERSON
    WITH
    5.

    SOLE VOTING POWER

     

    0

    6.

    SHARED VOTING POWER

     

    296,183 Shares

    7.

    SOLE DISPOSITIVE POWER

     

    0

    8.

    SHARED DISPOSITIVE POWER

     

    See Row 6 above

    9.

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

    See Row 6 above

    10.

    CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES

    o

     

    11.

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

     

    0.3%

    12.

    TYPE OF REPORTING PERSON

     

    OO; HC

           

     

     

     

     

     

    CUSIP No. 19249H103 13G Page 8 of 13 Pages

     

     

    1.

    NAME OF REPORTING PERSONS

     

    Kenneth Griffin

    2.

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

    (a)     o

    (b)     o

     

    3.

    SEC USE ONLY

     

    4.

    CITIZENSHIP OR PLACE OF ORGANIZATION

     

    U.S. Citizen

    NUMBER OF
    SHARES
    BENEFICIALLY
    OWNED BY
    EACH
    REPORTING
    PERSON
    WITH
    5.

    SOLE VOTING POWER

     

    0

    6.

    SHARED VOTING POWER

     

    2,047,286 Shares

    7.

    SOLE DISPOSITIVE POWER

     

    0

    8.

    SHARED DISPOSITIVE POWER

     

    See Row 6 above

    9.

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

    See Row 6 above

    10.

    CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES

    o

     

    11.

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

     

    1.8%

    12.

    TYPE OF REPORTING PERSON

     

    IN; HC

           

     

     

     

     

     

    CUSIP No. 19249H103 13G Page 9 of 13 Pages

     

     

    Item 1(a). Name of Issuer:
       
      Coherus BioSciences, Inc.
       
    Item 1(b). Address of Issuer’s Principal Executive Offices:
       
      333 Twin Dolphin Drive, Suite 600, Redwood City, CA 94065 United States 
       
    Item 2(a). Name of Person Filing:
       
      This Schedule 13G is being jointly filed by Citadel Advisors LLC (“Citadel Advisors”), Citadel Advisors Holdings LP (“CAH”), Citadel GP LLC (“CGP”), Citadel Securities LLC (“Citadel Securities”), Citadel Securities Group LP (“CALC4”), Citadel Securities GP LLC (“CSGP”) and Mr. Kenneth Griffin (collectively with Citadel Advisors, CAH, CGP, Citadel Securities, CALC4 and CSGP, the “Reporting Persons”) with respect to the Shares of the above-named issuer owned by Citadel Multi-Strategy Equities Master Fund Ltd., a Cayman Islands company (“CM”), CRBU Holdings LLC, a Delaware limited liability company (“CRBH”), and Citadel Securities.  Such owned Shares may include other instruments exercisable for or convertible into Shares.
       
      Citadel Advisors is the portfolio manager for CM. CAH is the sole member of Citadel Advisors. CGP is the general partner of CAH. CALC4 is the non-member manager of CRBH and Citadel Securities.  CSGP is the general partner of CALC4.  Mr. Griffin is the President and Chief Executive Officer of CGP, and owns a controlling interest in CGP and CSGP.
       
      The filing of this statement shall not be construed as an admission that any of the Reporting Persons is the beneficial owner of any securities covered by the statement other than the securities actually owned by such person (if any).
       
    Item 2(b). Address or Principal Business Office or, if none, Residence:
       
      The address of each of the Reporting Persons is Southeast Financial Center, 200 S. Biscayne Blvd., Suite 3300, Miami, Florida 33131.
       
    Item 2(c). Citizenship:
       
      Each of Citadel Advisors, CGP, Citadel Securities and CSGP is organized as a limited liability company under the laws of the State of Delaware.  Each of CALC4 and CAH is organized as a limited partnership under the laws of the State of Delaware.  Mr. Griffin is a U.S. citizen.
       
    Item 2(d). Title of Class of Securities:
       
      Common Stock, $0.0001 par value per share
       
    Item 2(e). CUSIP Number:
       
      19249H103

     

     

     

     

     

    CUSIP No. 19249H103 13G Page 10 of 13 Pages

     

     

    Item 3. If this statement is filed pursuant to §§ 240.13d-1(b), or 240.13d-2(b) or (c), check whether the person filing is a:
       
      (a) ¨ Broker or dealer registered under Section 15 of the Act (15 U.S.C. 78o);
      (b) ¨ Bank as defined in Section 3(a)(6) of the Act (15 U.S.C. 78c);
      (c) ¨ Insurance company as defined in Section 3(a)(19) of the Act (15 U.S.C. 78c);
      (d) ¨ Investment company registered under Section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
      (e) ¨ An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
      (f) ¨ An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
      (g) ¨ A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
      (h) ¨ A savings association as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
      (i) ¨ A church plan that is excluded from the definition of an investment company under Section 3(c)(14) of the Investment Company Act (15 U.S.C. 80a-3);
      (j) ¨ A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J);
      (k) ¨ Group, in accordance with § 240.13d-1(b)(1)(ii)(K).
             
      If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J), please specify the type of institution: ____________.
             
    Item 4. Ownership:
             
      A. Citadel Advisors LLC, Citadel Advisors Holdings LP and Citadel GP LLC
             
        (a) Each of Citadel Advisors LLC, Citadel Advisors Holdings LP and Citadel GP LLC may be deemed to beneficially own 1,751,103 Shares.
             
        (b) The number of Shares that each of Citadel Advisors LLC, Citadel Advisors Holdings LP and Citadel GP LLC may be deemed to beneficially own constitutes 1.6% of the Shares outstanding.
             
        (c) Number of Shares as to which such person has:
             
          (i) sole power to vote or to direct the vote:  0
             
          (ii) shared power to vote or to direct the vote:  1,751,103
             
          (iii) sole power to dispose or to direct the disposition of:  0
             
          (iv) shared power to dispose or to direct the disposition of:  1,751,103

     

     

     

     

     

    CUSIP No. 19249H103 13G Page 11 of 13 Pages

     

     

      B. Citadel Securities LLC
             
        (a) Citadel Securities LLC may be deemed to beneficially own 119,325 Shares.
           
        (b) The number of Shares that Citadel Securities LLC may be deemed to beneficially own constitutes 0.1% of the Shares outstanding.
           
        (c) Number of shares of Shares as to which such person has:
           
          (i) sole power to vote or to direct the vote:  0
             
          (ii) shared power to vote or to direct the vote:  119,325
             
          (iii) sole power to dispose or to direct the disposition of:  0
             
          (iv) shared power to dispose or to direct the disposition of:  119,325
             
      C. Citadel Securities Group LP and Citadel Securities GP LLC
             
        (a) Each of Citadel Securities Group LP and Citadel Securities GP LLC may be deemed to beneficially own 296,183 Shares.
           
        (b) The number of Shares that each of Citadel Securities Group LP and Citadel Securities GP LLC may be deemed to beneficially own constitutes 0.3% of the Shares outstanding.
           
        (c) Number of Shares as to which such person has:
           
          (i) sole power to vote or to direct the vote:  0
             
          (ii) shared power to vote or to direct the vote:  296,183
             
          (iii) sole power to dispose or to direct the disposition of:  0
             
          (iv) shared power to dispose or to direct the disposition of:  296,183
             

     

     

     

     

     

    CUSIP No. 19249H103 13G Page 12 of 13 Pages

     

     

      D. Kenneth Griffin
             
        (a) Mr. Griffin may be deemed to beneficially own 2,047,286 Shares.
           
        (b) The number of Shares that Mr. Griffin may be deemed to beneficially own constitutes 1.8% of the Shares outstanding.
           
        (c) Number of Shares as to which such person has:
           
          (i) sole power to vote or to direct the vote:  0
             
          (ii) shared power to vote or to direct the vote:  2,047,286
             
          (iii) sole power to dispose or to direct the disposition of:  0
             
          (iv) shared power to dispose or to direct the disposition of:  2,047,286

     

    Item 5. Ownership of Five Percent or Less of a Class:
       
      If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than 5 percent of the class of securities, check the following.   x
       
    Item 6. Ownership of More Than Five Percent on Behalf of Another Person:
       
      Not Applicable
       
    Item 7. Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on By the Parent Holding Company:
       
      Not Applicable
       
    Item 8. Identification and Classification of Members of the Group:
       
      Not Applicable
       
    Item 9. Notice of Dissolution of Group:
       
      Not Applicable
       
    Item 10. Certifications:
       
      By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect.

     

     

     

     

     

    CUSIP No. 19249H103 13G Page 13 of 13 Pages

     

     

    SIGNATURE

     

    After reasonable inquiry and to the best of its knowledge and belief, the undersigned certify that the information set forth in this statement is true, complete and correct.

     

    Dated February 14, 2024.

     

    CITADEL SECURITIES LLC   CITADEL ADVISORS LLC  
               
    By: /s/ Guy Miller   By: /s/ Seth Levy  
      Guy Miller, Authorized Signatory     Seth Levy, Authorized Signatory  
               
               
    CITADEL SECURITIES GROUP LP   CITADEL ADVISORS HOLDINGS LP  
               
    By: /s/ Guy Miller   By: /s/ Seth Levy  
      Guy Miller, Authorized Signatory     Seth Levy, Authorized Signatory  
               
               
    CITADEL SECURITIES GP LLC   CITADEL GP LLC  
               
    By: /s/ Guy Miller   By: /s/ Seth Levy  
      Guy Miller, Authorized Signatory     Seth Levy, Authorized Signatory  
               
               
          KENNETH GRIFFIN  
               
          By: /s/ Seth Levy  
            Seth Levy, attorney-in-fact*  

     

     

    _________________________

    * Seth Levy is signing on behalf of Kenneth Griffin as attorney-in-fact pursuant to a power of attorney previously filed with the Securities and Exchange Commission, and hereby incorporated by reference herein.  The power of attorney was filed as an attachment to a filing by Citadel Advisors LLC on Schedule 13G for Allakos Inc. on October 13, 2023.

     

     

     

    Get the next $CHRS alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $CHRS

    DatePrice TargetRatingAnalyst
    8/16/2024$4.00 → $1.50Buy → Neutral
    UBS
    11/17/2023$11.00Outperform
    Robert W. Baird
    11/8/2023Buy → Hold
    Maxim Group
    7/24/2023$12.00Buy
    Citigroup
    5/1/2023$24.00Buy
    Truist
    3/28/2023$11.00Neutral → Buy
    UBS
    6/14/2022$7.00Neutral
    UBS
    3/7/2022$15.00Overweight → Neutral
    JP Morgan
    More analyst ratings

    $CHRS
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    See more
    • FDA Approval for CIMERLI issued to COHERUS BIOSCIENCES INC

      Submission status for COHERUS BIOSCIENCES INC's drug CIMERLI (SUPPL-5) with active ingredient RANIBIZUMAB-EQRN has changed to 'Approval' on 05/21/2024. Application Category: BLA, Application Number: 761165, Application Classification:

      5/22/24 9:41:01 AM ET
      $CHRS
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • FDA Approval for LOQTORZI issued to COHERUS BIOSCIENCES INC

      Submission status for COHERUS BIOSCIENCES INC's drug LOQTORZI (SUPPL-1) with active ingredient TORIPALIMAB-TPZI has changed to 'Approval' on 04/22/2024. Application Category: BLA, Application Number: 761240, Application Classification:

      4/23/24 4:41:07 AM ET
      $CHRS
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • FDA Approval for UDENYCA issued to COHERUS BIOSCIENCES INC

      Submission status for COHERUS BIOSCIENCES INC's drug UDENYCA (SUPPL-15) with active ingredient PEGFILGRASTIM-CBQV has changed to 'Approval' on 12/22/2023. Application Category: BLA, Application Number: 761039, Application Classification:

      12/27/23 4:38:39 AM ET
      $CHRS
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $CHRS
    Leadership Updates

    Live Leadership Updates

    See more
    • Coherus BioSciences Appoints Rita Karachun, CPA, CGMA to its Board of Directors

      REDWOOD CITY, Calif., June 05, 2024 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. ((Coherus or the Company, NASDAQ:CHRS) today announced that Rita Karachun, CPA, CGMA, most recently Senior Vice President (SVP) and Global Controller for Merck & Co., Inc., (Merck) was appointed to its Board of Directors effective May 31, 2024. Ms. Karachun has nearly four decades of experience leading finance, accounting, and SEC reporting functions at multi-billion-dollar global companies. Her experience includes more than 17 years at Merck, where she held positions of increasing financial management responsibility. As Global Controller at Merck, Ms. Karachun managed a global team responsible for all accou

      6/5/24 9:00:00 AM ET
      $CHRS
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Coherus BioSciences Appoints Dr. Michael Ryan to its Board of Directors

       – Recognized biopharma commercialization and market access leader to support Coherus' strategic vision and multiple product launches – REDWOOD CITY, Calif., July 20, 2023 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (("Coherus" or the "Company", NASDAQ:CHRS), today announced the appointment to its Board of Directors of biopharma commercialization and market access expert Michael Ryan, Pharm. D. Dr. Ryan has four decades of experience working in academia and the biopharmaceutical industry bringing high-value therapeutics to patients. Dr. Ryan's distinguished career includes most recently serving as Senior Vice President and Head for U.S. and Worldwide Value, Access, Pricing and Health Ec

      7/20/23 4:04:53 PM ET
      $CHRS
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Coherus BioSciences Appoints Dr. Jill O'Donnell-Tormey to its Board of Directors

      - Dr. O'Donnell-Tormey is a cancer immunology key opinion leader with more than 30 years leading the Cancer Research Institute's efforts to advance cancer immunotherapies - REDWOOD CITY, Calif., May 11, 2022 (GLOBE NEWSWIRE) -- Coherus Biosciences, Inc. (("Coherus", NASDAQ:CHRS) today announced the appointment of cancer immunotherapy leader Jill O'Donnell-Tormey, Ph.D., to its Board of Directors. Dr. O'Donnell-Tormey will also serve on the Nominating and Corporate Governance Committee of the Board of Directors. Dr. O'Donnell-Tormey is the Chief Executive Officer and Director of Scientific Affairs of the Cancer Research Institute ("CRI"), a nonprofit organization dedicated exclusively to

      5/11/22 6:00:00 PM ET
      $CHRS
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $CHRS
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Coherus BioSciences downgraded by UBS with a new price target

      UBS downgraded Coherus BioSciences from Buy to Neutral and set a new price target of $1.50 from $4.00 previously

      8/16/24 7:33:26 AM ET
      $CHRS
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Robert W. Baird initiated coverage on Coherus BioSciences with a new price target

      Robert W. Baird initiated coverage of Coherus BioSciences with a rating of Outperform and set a new price target of $11.00

      11/17/23 7:37:50 AM ET
      $CHRS
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Coherus BioSciences downgraded by Maxim Group

      Maxim Group downgraded Coherus BioSciences from Buy to Hold

      11/8/23 9:19:04 AM ET
      $CHRS
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $CHRS
    Financials

    Live finance-specific insights

    See more
    • Coherus BioSciences Reports First Quarter 2025 Financial Results and Provides Business Update

      – Strategic transformation to innovative oncology completed in Q2 2025 – – Positive CHS-114 (anti-CCR8 antibody) Phase 1b dose expansion study data in patients with head and neck cancer presented at 2025 AACR Annual Meeting – – Additional CHS-114 Phase 1b studies in 2L gastric cancer and 2L HNSCC ongoing – – Enrollment ongoing in the Phase 2 randomized trial of casdozokitug/toripalimab/bevacizumab in 1L HCC, with first data readout expected in 1H 2026 – – LOQTORZI net revenue was $7.3 million and UDENYCA net revenue, now reflected in discontinued operations, was $31.5 million in Q1 2025  – – Conference call today at 5:00 p.m. Eastern Time – REDWOOD CITY, Calif., May 12, 2025 (GLOBE N

      5/12/25 4:15:13 PM ET
      $CHRS
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Coherus to Report First Quarter 2025 Financial Results on May 12, 2025

      REDWOOD CITY, Calif., May 05, 2025 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (("Coherus, NASDAQ:CHRS) today announced that its first quarter 2025 financial results will be released after market close on Monday, May 12, 2025. Starting at 5:00 p.m. EDT on May 12, 2025, Coherus' management team will host a conference call and webcast to discuss financial results and provide a general business update. A webcast replay will be available on https://investors.coherus.com following the conclusion of the live conference call. Conference Call Information When: Monday, May 12, 2025, starting at 5:00 p.m. Eastern Daylight Time To access the conference call, please pre-register through

      5/5/25 4:01:00 PM ET
      $CHRS
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Coherus Presents Promising Early Clinical Data from Phase 1 Dose Expansion Study of CHS-114 in Patients with Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma at AACR 2025

      – CHS-114 demonstrates clinical efficacy and proof of mechanism in HNSCC in combination with toripalimab – – Confirmed partial response in heavily pretreated PD-1 refractory patient supports expansion in HNSCC and gastric cancer in combination with toripalimab – – A second-line Phase 1 dose optimization study in HNSCC and gastric cancer is ongoing; results expected in the first half of 2026– – Coherus to host investor and analyst call with study investigator, Dr. Douglas Adkins, Washington University, today at 4:30 p.m. Eastern Time– REDWOOD CITY, Calif., April 28, 2025 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (("Coherus, NASDAQ:CHRS), today announced data from its ongoing Phase 1

      4/28/25 10:10:11 AM ET
      $CHRS
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $CHRS
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Coherus Completes Strategic Transformation to Coherus Oncology, Focusing Exclusively on Innovative Cancer Therapeutics

      REDWOOD CITY, Calif., May 30, 2025 (GLOBE NEWSWIRE) -- Coherus Oncology, Inc. ((Coherus Oncology, NASDAQ:CHRS), a commercial-stage innovative oncology company, formerly named Coherus BioSciences Inc., announced its name change today to better align with its exclusive focus on proprietary innovative immuno-oncology medicines. "The field of cancer immunotherapy has been reinvigorated by the promise and power of combination therapies. Coherus Oncology has the expertise and pipeline to become a significant player in this dynamic space and unlock the potential of these next-generation therapeutic approaches," said Jill O'Donnell-Tormey, Ph.D., Coherus Oncology board member. Dr. O'Donnell-Torme

      5/30/25 8:00:00 AM ET
      $CHRS
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Coherus Announces Clinical Collaboration with STORM Therapeutics to Evaluate STC-15 in Combination with LOQTORZI® (toripalimab-tpzi)

      REDWOOD CITY, Calif., May 27, 2025 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (("Coherus, NASDAQ:CHRS), today announced a clinical collaboration with STORM Therapeutics, Ltd. ("STORM") to evaluate STC-15, a METTL3 inhibitor, in combination with LOQTORZI (toripalimab-tpzi), a next-generation PD-1 inhibitor, in a Phase 1b/2 study for the treatment of non-small cell lung cancer (NSCLC), head and neck squamous cell carcinoma (HNSCC), melanoma and endometrial cancer. "We are excited to partner with STORM on the development of the LOQTORZI/STC-15 combination, with patient dosing underway in the Phase 1b/2 study," said Theresa LaVallee, Ph.D., Chief Scientific and Development Officer of Coher

      5/27/25 8:30:00 AM ET
      $CHRS
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Coherus BioSciences Reports First Quarter 2025 Financial Results and Provides Business Update

      – Strategic transformation to innovative oncology completed in Q2 2025 – – Positive CHS-114 (anti-CCR8 antibody) Phase 1b dose expansion study data in patients with head and neck cancer presented at 2025 AACR Annual Meeting – – Additional CHS-114 Phase 1b studies in 2L gastric cancer and 2L HNSCC ongoing – – Enrollment ongoing in the Phase 2 randomized trial of casdozokitug/toripalimab/bevacizumab in 1L HCC, with first data readout expected in 1H 2026 – – LOQTORZI net revenue was $7.3 million and UDENYCA net revenue, now reflected in discontinued operations, was $31.5 million in Q1 2025  – – Conference call today at 5:00 p.m. Eastern Time – REDWOOD CITY, Calif., May 12, 2025 (GLOBE N

      5/12/25 4:15:13 PM ET
      $CHRS
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $CHRS
    SEC Filings

    See more
    • Coherus BioSciences Inc. filed SEC Form 8-K: Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Regulation FD Disclosure, Financial Statements and Exhibits

      8-K - Coherus Oncology, Inc. (0001512762) (Filer)

      5/30/25 4:05:26 PM ET
      $CHRS
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Amendment: SEC Form SC TO-I/A filed by Coherus BioSciences Inc.

      SC TO-I/A - Coherus BioSciences, Inc. (0001512762) (Subject)

      5/15/25 4:46:03 PM ET
      $CHRS
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form 10-Q filed by Coherus BioSciences Inc.

      10-Q - Coherus BioSciences, Inc. (0001512762) (Filer)

      5/12/25 4:59:11 PM ET
      $CHRS
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $CHRS
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G filed by Coherus BioSciences Inc.

      SC 13G - Coherus BioSciences, Inc. (0001512762) (Subject)

      11/13/24 4:30:25 PM ET
      $CHRS
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Coherus BioSciences Inc.

      SC 13G/A - Coherus BioSciences, Inc. (0001512762) (Subject)

      7/23/24 8:23:56 AM ET
      $CHRS
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form SC 13G/A filed by Coherus BioSciences Inc. (Amendment)

      SC 13G/A - Coherus BioSciences, Inc. (0001512762) (Subject)

      5/22/24 7:27:00 PM ET
      $CHRS
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $CHRS
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Wahlstrom Mats sold $73,881 worth of shares (99,988 units at $0.74) (SEC Form 4)

      4 - Coherus BioSciences, Inc. (0001512762) (Issuer)

      5/28/25 5:12:50 PM ET
      $CHRS
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form 4 filed by Chief Financial Officer Mcmichael Bryan J

      4 - Coherus BioSciences, Inc. (0001512762) (Issuer)

      5/9/25 5:59:16 PM ET
      $CHRS
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form 4 filed by President & CEO Lanfear Dennis M

      4 - Coherus BioSciences, Inc. (0001512762) (Issuer)

      5/9/25 5:58:02 PM ET
      $CHRS
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care